



## Iveric Bio to Host a Zimura® R&D Symposium for Investors / Analysts on November 20, 2019

November 14, 2019

- Live Webcast to Begin at 8:00 a.m. Eastern Time -

NEW YORK--(BUSINESS WIRE)--Nov. 14, 2019--

[IVERIC bio, Inc.](#) (Nasdaq: ISEE) today announced details for its previously announced Zimura® R&D Symposium for Investors being held in New York, NY on Wednesday, November 20, 2019, from 8:00 a.m. to 10:00 a.m. ET.

The event will feature a presentation of the previously announced clinical trial results from the Company's Zimura® (avacincaptad pegol) program in geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) and will include discussions with retinal specialists and key opinion leaders in dry AMD. On October 28, 2019, the Company announced that Zimura met its pre-specified primary efficacy endpoint and reached statistical significance in a randomized, controlled clinical trial in GA secondary to dry AMD.

A live webcast will be available under "Events & Presentations" in the Investors section of the IVERIC bio website at <https://investors.ivericbio.com>. A replay of the webcast will be archived on IVERIC bio's website for at least 30 days following the presentation.

For more information, please contact Kathy Galante at [kathy.galante@ivericbio.com](mailto:kathy.galante@ivericbio.com) or 212-845-8231.

### About IVERIC bio

IVERIC bio is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. Vision is Our Mission. For more information on the Company please visit [www.ivericbio.com](http://www.ivericbio.com).

### Forward-looking Statements

*Any statements in this press release about IVERIC bio's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent IVERIC bio's views only as of the date of this press release. IVERIC bio anticipates that subsequent events and developments will cause its views to change. While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.*

### ISEE-G

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191114005114/en/>

Source: IVERIC bio, Inc.

Investors:  
IVERIC bio  
Kathy Galante, 212-845-8231  
Vice President, Investor Relations and Corporate Communications  
[kathy.galante@ivericbio.com](mailto:kathy.galante@ivericbio.com)

Or

Media:  
SmithSolve  
Alex Van Rees, 973-442-1555 ext. 111  
[alex.vanrees@smithsolve.com](mailto:alex.vanrees@smithsolve.com)